<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Mov Disord</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Mov Disord</journal-id><journal-title-group><journal-title>Journal of Clinical Movement Disorders</journal-title></journal-title-group><issn pub-type="epub">2054-7072</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26788334</article-id><article-id pub-id-type="pmc">4711001</article-id><article-id pub-id-type="publisher-id">23</article-id><article-id pub-id-type="doi">10.1186/2054-7072-1-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Testosterone level and the effect of levodopa and agonists in early Parkinson disease: results from the INSPECT cohort</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Okun</surname><given-names>Michael S</given-names></name><address><email>okun@neurology.ufl.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Samuel S</given-names></name><address><email>samwu@biostat.ufl.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Jennings</surname><given-names>Dana</given-names></name><address><email>djennings@mnimaging.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Marek</surname><given-names>Kenneth</given-names></name><address><email>kmarek@indd.org</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Rodriguez</surname><given-names>Ramon L</given-names></name><address><email>ramon.rodriguez@neurology.ufl.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Fernandez</surname><given-names>Hubert H</given-names></name><address><email>FERNANH@ccf.org</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Departments of Neurology, Neurosurgery and Psychiatry, McKnight Brain Institute, University of Florida, 100 S Newell Dr Rm-L3-101, Gainesville, 32611 FL USA </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>1</volume><elocation-id>8</elocation-id><history><date date-type="received"><day>25</day><month>6</month><year>2014</year></date><date date-type="accepted"><day>15</day><month>8</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Okun et al.; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>To determine if testosterone levels are influenced by dopaminergic therapy in Parkinson disease (PD) patients. Testosterone level has been reported to be low in patients with PD and other neurodegenerative diseases. In this study, we sought to determine whether dopaminergic therapy (i.e. levodopa and dopamine agonist) influenced testosterone levels. We used a cohort of consecutive male patients from the INSPECT trial--a multi-center, prospective, study that primarily investigated the effects of short-term treatment with pramipexole or levodopa on [<sup>123</sup>I] B-CIT SPECT imaging in early PD.</p></sec><sec><title>Methods</title><p>Testosterone levels were drawn on consenting male subjects with early PD who enrolled in the INSPECT trial at three study visits (baseline, 12&#x000a0;weeks post-treatment, and 8&#x02013;12 weeks post-washout). Subjects were randomized to: no treatment, pramipexole (up to 3&#x000a0;mg) or levodopa (up to 600&#x000a0;mg). Testosterone levels were obtained twice (prior to 10&#x000a0;AM) and averaged for each of three study visits.</p></sec><sec><title>Results</title><p>Thirty two male patients participated in this sub-study and there were no significant differences in disease characteristics in the 3 groups at baseline. Twenty-nine patients completed the follow-up visits and were suitable for analysis. There were statistically significant differences in the change in free testosterone level, increased in both the levodopa group and pramipexole group but decreased in the untreated group at 12-weeks post-treatment. There were no significant differences in the changes of UPDRS total or motor scores, although there was a strong trend toward improvement in motor scores. The testosterone level persisted in its increase only in the pramipexole group at the end of the washout period.</p></sec><sec><title>Conclusion</title><p>These preliminary data support the premise that dopaminergic medications do not reduce testosterone levels in early PD patients.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/2054-7072-1-8) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Testosterone</kwd><kwd>Parkinson&#x02019;s disease</kwd><kwd>Levodopa</kwd><kwd>Agonist</kwd><kwd>Medications</kwd><kwd>LH</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>There has been mounting evidence suggesting that inappropriately low plasma testosterone levels commonly exist in male patients with Parkinson disease (PD) [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>]. The relevance and underlying cause of this endocrine disturbance remain unknown. Additionally, replacement of testosterone has not to date been proven to significantly improve the motor and non-motor symptoms of these patients, though there have been anecdotal successes [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. Two main hypotheses have been proposed to explain the low testosterone levels: the levels are reduced by dopaminergic medications, or the testosterone level is a surrogate marker for pathology known to occur in the hypothalamus and in other relevant regions of the PD brain [<xref ref-type="bibr" rid="CR4">4</xref>]. We sought to examine the former hypothesis that dopaminergics may lower testosterone. In this study we utilized the INSPECT cohort of early PD subjects.</p></sec><sec id="Sec2"><title>Methods</title><p>Consecutive male PD patients (who fulfilled the UK Parkinson&#x02019;s Disease Brain Bank Criteria [<xref ref-type="bibr" rid="CR8">8</xref>]) enrolled in the INSPECT study had plasma free and total testosterone levels drawn. Patients had two testosterone levels (free and total) drawn prior to 10&#x000a0;AM during each study visit as described in a previous study [<xref ref-type="bibr" rid="CR4">4</xref>]. The levels for each subject at each study interval were averaged. Three scans- [123I]<inline-formula id="IEq1"><inline-graphic xlink:href="40734_2014_23_IEq1_HTML.gif"/></inline-formula>
-CIT and SPECT imaging were performed at baseline, 12&#x000a0;weeks following randomization to treatment group (levodopa [up to 600&#x000a0;mg/day], pramipexole [up to 3&#x000a0;mg/day], or no treatment), and 8&#x02013;12 weeks following medication washout (see Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Baseline levels and descriptive clinical variables were recorded, and changes from baseline to 12&#x000a0;weeks post-treatment, and changes from baseline to 8&#x02013;12 weeks post washout were compared between the three groups using analysis of variance (ANOVA).The University of Florida Institutional Review Board (IRB) through the parent INSPECT study approved the investigation, and each participant provided informed consent. <fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Study design.</bold>
</p></caption><graphic xlink:href="40734_2014_23_Fig1_HTML" id="d30e316"/></fig></p></sec><sec id="Sec3"><title>Results</title><p>Thirty-two consecutive male patients enrolled in the study and no differences in disease characteristics between groups were seen at baseline (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Twenty nine patients completed the follow-up visits and were suitable for analysis. Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> shows the mean and 95% confidence interval of the free testosterone level by time and group. The free testosterone level increased in both the levodopa group (change of 5.41&#x02009;&#x000b1;&#x02009;16.18) and pramipexole group (8.95&#x02009;&#x000b1;&#x02009;13.15), but decreased in the untreated group (&#x02212;13.92&#x02009;&#x000b1;&#x02009;23.12) from baseline to 12-week post-treatment. The between group difference reached a statistical significance of 0.019 with the use of an ANOVA test on the changes. There were no significant changes in UPDRS total or motor scores although there was a trend toward improvement in motor scores in both treatment groups compared to placebo. The increase in testosterone level persisted only the pramipexole group post-washout (see Tables&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Baseline characteristics of subjects in the study</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Group</th><th rowspan="2">N</th><th colspan="2">Age</th><th colspan="2">PD duration</th><th colspan="2">UPDRS M</th><th colspan="2">UPDRS T</th><th colspan="2">Free T</th><th colspan="2">Total T</th></tr><tr><th/><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th></tr></thead><tbody><tr><td>
<bold>Pramipexole</bold>
</td><td>
<bold>12</bold>
</td><td>68.83</td><td>13.13</td><td>2.44</td><td>1.67</td><td>21.92</td><td>5.62</td><td>30.75</td><td>8.25</td><td>63.69</td><td>25.24</td><td>386.32</td><td>151.73</td></tr><tr><td>
<bold>Levodopa</bold>
</td><td>
<bold>9</bold>
</td><td>70.33</td><td>9.31</td><td>2.11</td><td>1.45</td><td>17.44</td><td>7.09</td><td>25.22</td><td>10.51</td><td>55.03</td><td>18.18</td><td>361.06</td><td>146.71</td></tr><tr><td>
<bold>NoTreatment</bold>
</td><td>
<bold>11</bold>
</td><td>60.36</td><td>6.55</td><td>2.1</td><td>1.6</td><td>17.91</td><td>8.23</td><td>26.09</td><td>11.41</td><td>89.54</td><td>29.88</td><td>449.55</td><td>134.92</td></tr></tbody></table><table-wrap-foot><p>Legend: UPDRS M- Unified Parkinson Disease Rating Scale Motor Subsection, UPDRS T- Unified Parkinson Disease Rating Scale total score. Free T - free testosterone level; Total T - total testosterone level.</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Mean and 95% confidence interval of the free testosterone level by time and group.</bold>
</p></caption><graphic xlink:href="40734_2014_23_Fig2_HTML" id="d30e590"/></fig></p><table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Summary of changes from baseline to 12&#x000a0;weeks post treatment</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Group</th><th rowspan="2">N</th><th colspan="2">Total T</th><th colspan="2">UPDRS M</th><th colspan="2">UPDRS T</th></tr><tr><th/><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th></tr></thead><tbody><tr><td>
<bold>Pramipexole</bold>
</td><td>
<bold>10</bold>
</td><td>34.80</td><td>87.33</td><td>&#x02212;4.27</td><td>6.15</td><td>&#x02212;5.91</td><td>7.34</td></tr><tr><td>
<bold>Sinemet</bold>
</td><td>
<bold>9</bold>
</td><td>&#x02212;34.17</td><td>59.79</td><td>&#x02212;6.11</td><td>6.77</td><td>&#x02212;9.11</td><td>10.62</td></tr><tr><td>
<bold>NoTreatment</bold>
</td><td>
<bold>10</bold>
</td><td>21.80</td><td>74.71</td><td>0.90</td><td>6.64</td><td>&#x02212;0.50</td><td>8.87</td></tr><tr><td/><td/><td>p&#x02009;=&#x02009;0.12</td><td/><td>p&#x02009;=&#x02009;0.06</td><td/><td>p&#x02009;=&#x02009;0.12</td><td/></tr></tbody></table><table-wrap-foot><p>Legend: Total T - total testosterone level. UPDRS M- Unified Parkinson Disease Rating Scale Motor Subsection; UPDRS T- Unified Parkinson Disease Rating Scale total score. Free testosterone measured in pg/ml, and total testosterone in ng/dl.</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Summary of changes from baseline to the end of washout period</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Group</th><th rowspan="2">N</th><th colspan="2">Total T</th><th colspan="2">UPDRS M</th><th colspan="2">UPDRS T</th></tr><tr><th/><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th></tr></thead><tbody><tr><td>
<bold>Pramipexole</bold>
</td><td>
<bold>7</bold>
</td><td>103.79</td><td>49.47</td><td>0.89</td><td>5.62</td><td>1.56</td><td>5.29</td></tr><tr><td>
<bold>Sinemet</bold>
</td><td>
<bold>7</bold>
</td><td>&#x02212;13.21</td><td>40.27</td><td>1.86</td><td>6.54</td><td>1.71</td><td>7.93</td></tr><tr><td>
<bold>NoTreatment</bold>
</td><td>
<bold>9</bold>
</td><td>100.78</td><td>104.58</td><td>0.78</td><td>8.63</td><td>&#x02212;0.22</td><td>11.39</td></tr><tr><td/><td/><td>p&#x02009;=&#x02009;0.01</td><td/><td>p&#x02009;=&#x02009;0.95</td><td/><td>p&#x02009;=&#x02009;0.88</td><td/></tr></tbody></table><table-wrap-foot><p>Legend: Total T - total testosterone level. UPDRS M- Unified Parkinson Disease Rating Scale Motor Subsection; UPDRS T- Unified Parkinson Disease Rating Scale total score. Free testosterone measured in pg/ml, and total testosterone in ng/dl.</p></table-wrap-foot></table-wrap></sec><sec id="Sec4"><title>Discussion and conclusions</title><p>These results suggest that neither levodopa nor pramipexole decrease testosterone level in early PD. The observation that the untreated group experienced further lowering of free testosterone levels lends support to the hypothesis that testosterone decline in PD may be a result of disease-specific factors, and that the decline is less likely iatrogenically induced by dopaminergic medications. It is not entirely clear why the increase in free testosterone levels persisted in the dopamine agonist group post-washout. Dopamine agonists have been used in the treatment of prolactinoma, because dopamine is a natural inhibitor of prolactin [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Prolactin lowers leutenizing hormone (LH) which in turn lowers testosterone level [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. Thus, dopamine agonists may theoretically increase testosterone levels by inhibiting prolactin. This point will need further clarification.</p><p>Sinhamahapatra and Kirschner in 1971 published a detailed analysis of the effect of levodopa on testosterone level [<xref ref-type="bibr" rid="CR17">17</xref>]. They sought in their study to answer the question as to whether levodopa stimulated LH production and Leydig cell activity. They utilized an electron capture gas liquid chromatographor, an older technique now considered less accurate when compared to more modern techniques for measuring testosterone. Seven PD men staged using an older system devised by Leon were included in the analysis . Very high doses of levodopa were used (2&#x02013;6 grams/day). There were other methodological limitations including baseline normal levels in all patients enrolled (&#x0003e;325&#x000a0;ng/ml), and 2/7 PD patients who did not improve on levodopa. One interesting aspect of their study was the calculation of testosterone production and metabolism, as well as the measurement of LH. The study concluded that levodopa did not have an impact on plasma testosterone or LH [<xref ref-type="bibr" rid="CR17">17</xref>]. Despite methodological limitations this data is supportive of our findings.</p><p>We suspect based on our results that the finding of low testosterone in PD patients is indicative of intrinsic PD pathology. It is well known that Lewy Body pathology is present in PD patients at post-mortem examination, and lesions includes hypothalamic involvement [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. Braak has shown that this hypothalamic pathology may be present relatively early in the course of PD [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. We propose this as a plausible explanation for the low testosterone levels.</p><p>There were several limitations in this study that should be addressed in future investigations. These limitations included a small sample size, the lack of non-PD controls, the use of early PD patients, differences between free and total testosterone levels, and observed changes in testosterone level were small and not likely clinically relevant. There were changes seen between free testosterone and total testosterone and this highlighted difficulties in laboratory measurements. Most experts use a free or bioavailable testosterone level as the gold standard rather than utilizing both a free and total testosterone level [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. Despite these limitations we conclude as did Sinhamahapatra, that dopaminergics are probably not the cause of low testosterone in PD. Clinicians should not assume that low testosterone levels are an effect of PD medications. There is currently no evidence that checking a testosterone level prior to dopaminergic therapy will be clinically useful. We suggest that future research on this topic should focus on disease related factors as the potential culprits in the low testosterone PD story, however a larger study of the effects of medication can confirm our results.</p></sec></body><back><app-group><app id="App1"><sec id="Sec5"><title>Authors&#x02019; original submitted files for images</title><p>Below are the links to the authors&#x02019; original submitted files for images.<media position="anchor" xlink:href="40734_2014_23_MOESM1_ESM.tiff" id="MOESM1"><caption><p>Authors&#x02019; original file for figure 1</p></caption></media><media position="anchor" xlink:href="40734_2014_23_MOESM2_ESM.tiff" id="MOESM2"><caption><p>Authors&#x02019; original file for figure 2</p></caption></media></p></sec></app></app-group><fn-group><fn><p><bold>Competing interests</bold></p><p>Dr. Okun serves as a consultant for the National Parkinson Foundation, and has received research grants from NIH, NPF, the Michael J. Fox Foundation, the Parkinson Alliance, Smallwood Foundation, the Bachmann-Strauss Foundation, the Tourette Syndrome Association, and the UF Foundation. Dr. Okun has previously received honoraria, but in the past &#x0003e;60&#x000a0;months has received no support from industry. Dr. Okun has received royalties for publications with Demos, Manson, Amazon, Smashwords, Books4Patients, and Cambridge (movement disorders books). Dr. Okun is an associate editor for New England Journal of Medicine Journal Watch Neurology. Dr. Okun has participated in CME and educational activities on movement disorders (in the last 36) months sponsored by PeerView, Prime, Quantia, Henry Stewart, and by Vanderbilt University. The institution and not Dr. Okun receives grants from Medtronic, Abbvie, and ANS/St. Jude, and the PI has no financial interest in these grants. Dr. Okun has participated as a site PI and/or co-I for several NIH, foundation, and industry sponsored trials over the years but has not received honoraria. The other authors report no other relevant competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>MSO participated in study conception. MSO, SSW, DK, JM, RLR and HHF participated in study design. MSO wrote the first draft of the manuscript. MSO, SSW, DK, JM, RLR and HHF added critical revisions to the manuscript. All authors have read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to acknowledge the support of the National Parkinson Foundation Center of Excellence at the University of Florida, the UF Foundation, and the NIH NS044997.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>KL</given-names></name><name><surname>Moro-De-Casillas</surname><given-names>ML</given-names></name><name><surname>Amick</surname><given-names>MM</given-names></name><name><surname>Borek</surname><given-names>LL</given-names></name><name><surname>Friedman</surname><given-names>JH</given-names></name></person-group><article-title>Testosterone not associated with violent dreams or REM sleep behavior disorder in men with Parkinson&#x02019;s</article-title><source>Mov Disord</source><year>2007</year><volume>22</volume><fpage>411</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1002/mds.21339</pub-id><pub-id pub-id-type="pmid">17230453</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okun</surname><given-names>MS</given-names></name><name><surname>Crucian</surname><given-names>GP</given-names></name><name><surname>Fischer</surname><given-names>L</given-names></name><name><surname>Walter</surname><given-names>BL</given-names></name><name><surname>Testa</surname><given-names>CM</given-names></name><name><surname>Vitek</surname><given-names>JL</given-names></name><name><surname>DeLong</surname><given-names>MR</given-names></name><name><surname>Hanfelt</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name></person-group><article-title>Testosterone deficiency in a Parkinson&#x02019;s disease clinic: results of a survey</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2004</year><volume>75</volume><issue>1</issue><fpage>165</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">14707335</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okun</surname><given-names>MS</given-names></name><name><surname>DeLong</surname><given-names>MR</given-names></name><name><surname>Hanfelt</surname><given-names>J</given-names></name><name><surname>Gearing</surname><given-names>M</given-names></name><name><surname>Levey</surname><given-names>A</given-names></name></person-group><article-title>Plasma testosterone levels in Alzheimer and Parkinson diseases</article-title><source>Neurology</source><year>2004</year><volume>62</volume><fpage>411</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000106840.72938.84</pub-id><pub-id pub-id-type="pmid">14872022</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okun</surname><given-names>MS</given-names></name><name><surname>Fernandez</surname><given-names>HH</given-names></name><name><surname>Rodriguez</surname><given-names>RL</given-names></name><name><surname>Romrell</surname><given-names>J</given-names></name><name><surname>Suelter</surname><given-names>M</given-names></name><name><surname>Munson</surname><given-names>S</given-names></name><name><surname>Louis</surname><given-names>ED</given-names></name><name><surname>Mulligan</surname><given-names>T</given-names></name><name><surname>Foster</surname><given-names>PS</given-names></name><name><surname>Shenal</surname><given-names>BV</given-names></name><name><surname>Armaghani</surname><given-names>SJ</given-names></name><name><surname>Jacobson</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Crucian</surname><given-names>G</given-names></name></person-group><article-title>Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study</article-title><source>Arch Neurol</source><year>2006</year><volume>63</volume><issue>5</issue><fpage>729</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1001/archneur.63.5.729</pub-id><pub-id pub-id-type="pmid">16682542</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okun</surname><given-names>MS</given-names></name><name><surname>McDonald</surname><given-names>WM</given-names></name><name><surname>DeLong</surname><given-names>MR</given-names></name></person-group><article-title>Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity</article-title><source>Arch Neurol</source><year>2002</year><volume>59</volume><fpage>807</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1001/archneur.59.5.807</pub-id><pub-id pub-id-type="pmid">12020264</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okun</surname><given-names>MS</given-names></name><name><surname>Walter</surname><given-names>BL</given-names></name><name><surname>McDonald</surname><given-names>WM</given-names></name><name><surname>Tenover</surname><given-names>JL</given-names></name><name><surname>Green</surname><given-names>J</given-names></name><name><surname>Juncos</surname><given-names>JL</given-names></name><name><surname>DeLong</surname><given-names>MR</given-names></name></person-group><article-title>Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson disease</article-title><source>Arch Neurol</source><year>2002</year><volume>59</volume><issue>11</issue><fpage>1750</fpage><lpage>1753</lpage><pub-id pub-id-type="doi">10.1001/archneur.59.11.1750</pub-id><pub-id pub-id-type="pmid">12433262</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>E</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Burnet</surname><given-names>R</given-names></name></person-group><article-title>Testosterone improves motor function in Parkinson&#x02019;s disease</article-title><source>J Clin Neurosci</source><year>2006</year><volume>13</volume><fpage>133</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.jocn.2005.02.014</pub-id><pub-id pub-id-type="pmid">16410216</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>AJ</given-names></name><name><surname>Daniel</surname><given-names>SE</given-names></name><name><surname>Kilford</surname><given-names>L</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name></person-group><article-title>Accuracy of clinical diagnosis of idiopathic Parkinson&#x02019;s disease: a clinico-pathological study of 100 cases</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1992</year><volume>55</volume><fpage>181</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1136/jnnp.55.3.181</pub-id><pub-id pub-id-type="pmid">1564476</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molitch</surname><given-names>ME</given-names></name></person-group><article-title>Pharmacologic resistance in prolactinoma patients</article-title><source>Pituitary</source><year>2005</year><volume>8</volume><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1007/s11102-005-5085-2</pub-id><pub-id pub-id-type="pmid">16411068</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimon</surname><given-names>I</given-names></name><name><surname>Benbassat</surname><given-names>C</given-names></name><name><surname>Hadani</surname><given-names>M</given-names></name></person-group><article-title>Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men</article-title><source>Eur J Endocrinol</source><year>2007</year><volume>156</volume><fpage>225</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1530/EJE-06-0646</pub-id><pub-id pub-id-type="pmid">17287412</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other"><bold>Treatment of androgen deficiency in the aging male</bold><italic>Fertil Steril</italic> 2006, <bold>86:</bold> S236&#x02013;240.</mixed-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haren</surname><given-names>MT</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Tariq</surname><given-names>SH</given-names></name><name><surname>Wittert</surname><given-names>GA</given-names></name><name><surname>Morley</surname><given-names>JE</given-names></name></person-group><article-title>Andropause: a quality-of-life issue in older males</article-title><source>Med Clin North Am</source><year>2006</year><volume>90</volume><fpage>1005</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1016/j.mcna.2006.06.001</pub-id><pub-id pub-id-type="pmid">16962854</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harman</surname><given-names>SM</given-names></name></person-group><article-title>Testosterone in older men after the Institute of Medicine Report: where do we go from here?</article-title><source>Climacteric</source><year>2005</year><volume>8</volume><fpage>124</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1080/13697130500118001</pub-id><pub-id pub-id-type="pmid">16096168</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaku</surname><given-names>H</given-names></name><name><surname>Saika</surname><given-names>T</given-names></name><name><surname>Tsushima</surname><given-names>T</given-names></name><name><surname>Ebara</surname><given-names>S</given-names></name><name><surname>Senoh</surname><given-names>T</given-names></name><name><surname>Yamato</surname><given-names>T</given-names></name><name><surname>Nasu</surname><given-names>Y</given-names></name><name><surname>Kumon</surname><given-names>H</given-names></name></person-group><article-title>Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer</article-title><source>Prostate</source><year>2006</year><volume>66</volume><issue>4</issue><fpage>439</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1002/pros.20341</pub-id><pub-id pub-id-type="pmid">16329145</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morley</surname><given-names>JE</given-names></name></person-group><article-title>Androgens and aging</article-title><source>Maturitas</source><year>2001</year><volume>38</volume><fpage>61</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/S0378-5122(00)00192-4</pub-id><pub-id pub-id-type="pmid">11311591</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morley</surname><given-names>JE</given-names></name><name><surname>Haren</surname><given-names>MT</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Kevorkian</surname><given-names>R</given-names></name><name><surname>Perry</surname><given-names>HM</given-names><suffix>3rd</suffix></name></person-group><article-title>Testosterone, aging and quality of life</article-title><source>J Endocrinol Invest</source><year>2005</year><volume>28</volume><fpage>76</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">16042363</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinhamahapatra</surname><given-names>SB</given-names></name><name><surname>Kirschner</surname><given-names>MA</given-names></name></person-group><article-title>Effect of L-dopa on testosterone and luteinizing hormone production</article-title><source>J Clin Endocrinol Metab</source><year>1972</year><volume>34</volume><fpage>756</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1210/jcem-34-4-756</pub-id><pub-id pub-id-type="pmid">5012777</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name></person-group><article-title>Pathoanatomy of Parkinson&#x02019;s disease</article-title><source>J Neurol</source><year>2000</year><volume>247</volume><issue>Suppl 2</issue><fpage>II3</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">10991663</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Bratzke</surname><given-names>H</given-names></name><name><surname>Hamm-Clement</surname><given-names>J</given-names></name><name><surname>Sandmann-Keil</surname><given-names>D</given-names></name><name><surname>Rub</surname><given-names>U</given-names></name></person-group><article-title>Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson&#x02019;s disease (preclinical and clinical stages)</article-title><source>J Neurol</source><year>2002</year><volume>249</volume><issue>Suppl 3</issue><fpage>III/1-5</fpage><pub-id pub-id-type="pmid">12528692</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Rub</surname><given-names>U</given-names></name><name><surname>de Vos</surname><given-names>RA</given-names></name><name><surname>Jansen Steur</surname><given-names>EN</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name></person-group><article-title>Staging of brain pathology related to sporadic Parkinson&#x02019;s disease</article-title><source>Neurobiol Aging</source><year>2003</year><volume>24</volume><fpage>197</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/S0197-4580(02)00065-9</pub-id><pub-id pub-id-type="pmid">12498954</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Ghebremedhin</surname><given-names>E</given-names></name><name><surname>Rub</surname><given-names>U</given-names></name><name><surname>Bratzke</surname><given-names>H</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name></person-group><article-title>Stages in the development of Parkinson&#x02019;s disease-related pathology</article-title><source>Cell Tissue Res</source><year>2004</year><volume>318</volume><fpage>121</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1007/s00441-004-0956-9</pub-id><pub-id pub-id-type="pmid">15338272</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jellinger</surname><given-names>KA</given-names></name></person-group><article-title>Post mortem studies in Parkinson&#x02019;s disease&#x02013;is it possible to detect brain areas for specific symptoms?</article-title><source>J Neural Transm Suppl</source><year>1999</year><volume>56</volume><fpage>1</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1007/978-3-7091-6360-3_1</pub-id><pub-id pub-id-type="pmid">10370901</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morley</surname><given-names>JE</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Haren</surname><given-names>MT</given-names></name></person-group><article-title>Frailty and hormones</article-title><source>Rev Endocr Metab Disord</source><year>2005</year><volume>6</volume><fpage>101</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1007/s11154-005-6722-9</pub-id><pub-id pub-id-type="pmid">15843881</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>RS</given-names></name><name><surname>Salazar</surname><given-names>JA</given-names></name></person-group><article-title>Risks of testosterone replacement therapy in ageing men</article-title><source>Expert Opin Drug Saf</source><year>2004</year><volume>3</volume><fpage>599</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1517/14740338.3.6.599</pub-id><pub-id pub-id-type="pmid">15500418</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermeulen</surname><given-names>A</given-names></name></person-group><article-title>Androgen supplementation in elderly males: is dihydrotestosterone to be preferred?</article-title><source>Aging Male</source><year>2004</year><volume>7</volume><fpage>325</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1080/13685530400016672</pub-id><pub-id pub-id-type="pmid">15799129</pub-id></element-citation></ref></ref-list></back></article>